<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263767</url>
  </required_header>
  <id_info>
    <org_study_id>RC16_0435</org_study_id>
    <nct_id>NCT03263767</nct_id>
  </id_info>
  <brief_title>Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC</brief_title>
  <acronym>CYRIC</acronym>
  <official_title>Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute or chronic graft versus host disease is still the major complication of stem cells&#xD;
      transplantation regarding morbidity and mortality.&#xD;
&#xD;
      Recently, high dose cyclophosphamide utilization early after post-transplantation (day+ 3 and&#xD;
      +4) not only for patients with HLA- haploidentical donor but also for patients with Human&#xD;
      Leukocyte Antigen (HLA)-compatible donor, showed a great control of graft versus host disease&#xD;
      after transplantation, allowing to consider stopping immunosuppressive treatment after the&#xD;
      transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil). Indeed, this step has&#xD;
      already been completed in myeloablative transplantation in adult patients.&#xD;
&#xD;
      This approach could enable to avoid in the end several complications related to long term&#xD;
      immunosuppressive drugs administration, while promoting quicker immunity recovery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BALTIMORE conditioning regiment will be used in this study with peripheral stem cell&#xD;
      transplantation and fludarabine will be replaced by clofarabine for myeloid diseases (Acute&#xD;
      Myeloide Leukemia, Myelodysplasia , myelofibrosis, Chronic Myeoloid Leukemia..) because of&#xD;
      better antitumoral activity in this setting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade 3 and 4 acute GVHD cortico-resistant</measure>
    <time_frame>100 days after transplantation</time_frame>
    <description>acute GVHD will be evaluated from International Mount Sinai criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>one year</time_frame>
    <description>number of days in aplasia (neutrophils&lt; 0.5 Giga/L and platelets&lt;20 G/l, number of transfusions (red blood and platelets)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>one year</time_frame>
    <description>chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival (DFS)</measure>
    <time_frame>one year, the last follow-up visit</time_frame>
    <description>blood and bone marrow analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>one year, the last follow-up visit</time_frame>
    <description>clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft and relapse free survival</measure>
    <time_frame>one year</time_frame>
    <description>time between Day O and relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic GVHD</measure>
    <time_frame>one year</time_frame>
    <description>chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non relapse mortality (NRM)</measure>
    <time_frame>last follow-up visit</time_frame>
    <description>number of death unrelated to relapse or disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism</measure>
    <time_frame>1, 2, 3, 6 and 12 months after transplantation</time_frame>
    <description>proportion of full and mixed donor chimerism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution</measure>
    <time_frame>3, 6 and 12 months after transplantation</time_frame>
    <description>lymphocytes, monocytes, T4, T8, Natural Killer (NK), B cells rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of ghost factors associated with GVHD</measure>
    <time_frame>one year</time_frame>
    <description>Statistical Models to Identify Subjects with Ghost Prognosis Factors Nguyen JM. 2015</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of grade 3 and 4 after transplantation</measure>
    <time_frame>one year</time_frame>
    <description>time of occurring and frequency of grade 3 and grade 4 adverse events (CTCAE criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections frequency</measure>
    <time_frame>one year</time_frame>
    <description>time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare OS between patients with ATG and patients without ATG</measure>
    <time_frame>one year, last follow-up visit</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare grade 2-4 and 3-4 acute GVHD between patients with ATG and patients without ATG</measure>
    <time_frame>one year</time_frame>
    <description>acute GVHD will be evaluated from International Mount Sinai criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare chronic GVHD between patients with ATG and patients without ATG</measure>
    <time_frame>one year</time_frame>
    <description>chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare DFS between patients with ATG and patients without ATG</measure>
    <time_frame>one year, last follow-up visit</time_frame>
    <description>DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare Relapse between patients with ATG and patients without ATG</measure>
    <time_frame>one year, last follow-up visit</time_frame>
    <description>Relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare NRM between patients with ATG and patients without ATG</measure>
    <time_frame>one year, last follow-up visit</time_frame>
    <description>NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare Infections frequency between patients with ATG and patients without ATG</measure>
    <time_frame>one year</time_frame>
    <description>time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with lymphoid hemopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with myeloid hemopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m² Intravenous 5 days from Day-6 to Day-2</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>30 mg/m² Intravenous 5 days from Day-6 to Day-2</description>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Full body irradiation</intervention_name>
    <description>2 grays at Day-1</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14 mg/kg intravenous 2 days at Day - 6 and day -5</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>50 mg/kg intravenous 2 days at day +3 and day +4</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
    <other_name>hight dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
    <other_name>graft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nuclear cells</intervention_name>
    <description>CD3+ cells if needed after transplantation</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>LYMPHOID HEMOPATHY without ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY without ATG</arm_group_label>
    <other_name>Donor Lymphocytes Injection (DLI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin Injectable Product</intervention_name>
    <description>At day -2 2.5 mg/kg for patients inclued after 14 dec 2020</description>
    <arm_group_label>LYMPHOID HEMOPATHY witH ATG</arm_group_label>
    <arm_group_label>MYELOID HEMOPATHY with ATG</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults ≤ 70 years old&#xD;
&#xD;
          -  indication to stem cells transplantation with reduced-intensity conditioning regimen&#xD;
&#xD;
          -  with a HLA-compatible familial 10/10 or non-familial donor&#xD;
&#xD;
          -  Written signed informed consent form&#xD;
&#xD;
          -  woman with childbearing potential under efficient control birth method during the&#xD;
             trial and up to 12 months after cyclophosphamide stop&#xD;
&#xD;
          -  men under efficient control birth method during the trial and up to 6 months after&#xD;
             cyclophosphamide stop&#xD;
&#xD;
          -  Negative serology to B and C hepatitis and to HIV&#xD;
&#xD;
          -  Affiliated to social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Eligible to myeloablative contioning regimen&#xD;
&#xD;
          -  Other progressive malignancy disease or history of prior other malignancy in the last&#xD;
             two years, with the exception of: curatively treated basal cell carcinoma or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  Progressive mental illness disease&#xD;
&#xD;
          -  Pregnant or Breastfeeding woman&#xD;
&#xD;
          -  woman with childbearing potential without any efficient control birth&#xD;
&#xD;
          -  Serious concomitant infection and not controlled&#xD;
&#xD;
          -  Contra-indications to allogenic transplantation, especially:&#xD;
&#xD;
               -  Cardiac: left ventricular ejection fraction &lt;45% assessed by transthoracic&#xD;
                  echography or isotopic method (isotopic gamma-angiography)&#xD;
&#xD;
               -  Respiratory: DLCO limiting fludarabine and busulfan use (DLCO&lt; 40% of theorical&#xD;
                  value)&#xD;
&#xD;
               -  Renal: creatinine clearance &lt; 60ml/min (MDRD method)&#xD;
&#xD;
               -  Hepatic: transaminases &gt;5 Uper Per Normal (UPN) or bilirubin&gt; 2 UPN&#xD;
&#xD;
          -  Contra-indications to cyclophosphamide:&#xD;
&#xD;
               -  Urinary tract infections&#xD;
&#xD;
               -  Acute urothelial toxicity due to cytotoxic chemotherapy or to radiotherapy&#xD;
&#xD;
               -  Obstruction of urines flow&#xD;
&#xD;
               -  Pre-existing hemorrhagic cystitis&#xD;
&#xD;
               -  Yellow fever vaccination&#xD;
&#xD;
          -  Cardiac condition preventing high dose cyclophosphamide utilization :&#xD;
&#xD;
               -  New York Heart Association (NYHA) functional class II, III or IV&#xD;
&#xD;
               -  Rhythmic, valvular or ischemic cardiomyopathy&#xD;
&#xD;
          -  Minor&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Patient under judicial protection&#xD;
&#xD;
          -  Known or suspected hypersensitivity to cyclophosphamide&#xD;
&#xD;
          -  Known or suspected hypersensitivity to rabbit proteins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrice CHEVALLIER, MD-PHD</last_name>
    <phone>+33 2 40 08 39 94</phone>
    <email>patrice.chevallier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes Uh</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PATRICE CHEVALLIER</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2017</study_first_submitted>
  <study_first_submitted_qc>August 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral haemopoietic stem cell transplant</keyword>
  <keyword>High dose cyclophosphamide</keyword>
  <keyword>acute GVHD</keyword>
  <keyword>allogenic transplantation</keyword>
  <keyword>RIC (reduced-intensity conditioning)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

